Jan 16, 2019 - Defensive equities could ride out market unpredictability.
Dec 26, 2018 - Neurocrine Biosciences announced that its phase 2b study using Ingrezza to treat patients with Tourette Syndrome failed to meet the primary endpoint.Ingrezza has already been approved by the FDA to tr
Dec 20, 2018 - I'm initiating a long-term core position in Neurocrine Biosciences following a ~20% shave post Tourette syndrome failure and a ~40% shave from 52-week highs.Wholly-owned Ingrezza, for the treatment of
Dec 13, 2018 - Neurocrine announced that its T-Force GOLD study of Ingrezza in pediatric Tourette's had failed.The failure isn't a complete surprise, but removes Neurocrine's last late-stage pipeline asset from cons
Dec 12, 2018 - Find out which of these companies warned about its future results.
Nov 05, 2018 - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2018 Results Earnings Conference Call November 5, 2018, 04:30 PM ET Executives Jane Sorensen - Executive Assistant Kevin Gorman - Chief Executive Officer
Nov 05, 2018 - The following slide deck was published by Neurocrine Biosciences, Inc. in conjunction with their 2018 Q3 earnings call.
Nov 05, 2018 - Top Gainers: ELF +18.5%. CVGI +12.8%. FN +11.3%. ATUS +8.8%. LASR +5.7%. Top Losers: FTDR -8.9%. NEOS -7.8% NBIX -6.2%. IIN -6.2%. THC -5.2%.
Nov 02, 2018 - We see how things are shaping up for the four pharma/biotech companies, which are scheduled to release second-quarter earnings on Nov 5.
Oct 29, 2018 - Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.